Dr. Mirshahidi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11234 Anderson St
Loma Linda, CA 92354Phone+1 909-558-2262Fax+1 909-651-5939
Summary
- Dr. Hamid Mirshahidi is an oncologist in Loma Linda, CA and is affiliated with Loma Linda University Medical Center. He received his medical degree from Marmara University Faculty of Medicine and has been in practice 25 years. He specializes in hematologic oncology.
Education & Training
- West Virginia UniversityFellowship, Hematology and Medical Oncology, 2002 - 2005
- Trinity Health Oakland/Wayne State UniversityResidency, Internal Medicine, 1999 - 2002
- Marmara Univ- Fac MedClass of 1992
Certifications & Licensure
- CA State Medical License 2002 - 2026
- MI State Medical License 1999 - 2018
- WV State Medical License 2002 - 2017
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Best Doctors in Inland Empire 2008
- Margaret J. Albrink Research Award West Virginia University, 2005
Clinical Trials
- S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride Start of enrollment: 2011 Nov 15
- Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
- A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
- Join now to see all
Publications & Presentations
PubMed
- 93 citationsNovel targeted therapeutics: inhibitors of MDM2, ALK and PARPYuan Yuan, Yu Min Liao, Chung-Tsen Hsueh, Hamid R. Mirshahidi
Journal of Hematology & Oncology. 2011-04-20 - 36 citationsConservative management of nivolumab-induced pericardial effusion: a case report and review of literatureShagufta Shaheen, Hamid R. Mirshahidi, Gayathri Nagaraj, Chung-Tsen Hsueh
Experimental Hematology & Oncology. 2018-05-08 - 32 citationsSuicide in cancer patients in California, 1997-2006.Kiumarss Nasseri, Paul K. Mills, Hamid R. Mirshahidi, Lawrence H. Moulton
Archives of Suicide Research. 2012-11-08
Journal Articles
- Nivolumab-induced pericardial effusionSheehen S, Mirshahidi HR, Nagaraj G, Hsueh CT, Lung Cancer. Exp Hematol Oncol, 1/1/2018
- Metastatic Biomarkers In Synovial SarcomaNecochea-Campion RD, Zuckerman LM; Mirshahidi HR, Khosrowpour S, Chen CS, Mirshahidi S, Biomarker Research, 1/7/2017
- SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete res...Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN, Breast Cancer Res Treat., 1/1/2016
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Evidence-based conclusions and inclinations of pemetrexed, taxane and bevacizumab in advanced lung cancer.Shaheen S, Ji L, Morgan2JW, Otoukesh S, Mirshahidi HR., Journal of Thoracic Oncology. The 8th European Lung Cancer Congress (ELCC), Geneva, Switzerland, 1/11/2018
- EGFR reporting in stage IV adenocarcinoma of the lung: Demographic predictors of EGFR testing and survival.Shaheen S, Ji L, Morgan2JW, Otoukesh S, Mirshahidi S, Mirshahidi HR, ASCO, Chicago, 1/1/2018
- Antiproliferative effect of bupivacaine on patient-derived sarcoma cells.Zuckerman LM, Mirshahidi HR, Williams NL, Elsissy J, Shields TG, Otoukesh S, Mirshahidi S., The Connective Tissue Oncology Society., Rome, Italy, 1/1/2018
- Join now to see all
Lectures
- The effect of non-steroidal anti-inflammatory drugs on osteosarcoma cellsLoma Linda, CA - 1/1/2019
- Personalized Treatment for Lung CancerLoma Linda University - 1/1/2011
- Suicide in Cancer Patients with Carcinoma of Lung and Bronchus in California, 1997-2006Amsterdam, Netherland - 1/1/2011
- Join now to see all
Other
- Factors influencing the incidence of diarrhea in rural areas of the province Of Khorassan, Iran.Mirshahidi HR
University of Teheran, School of Medicine. Tehran, Iran - 1/1/1993 - Sex education for young adults in Istanbul.Mirshahidi HR.
School of Medicine, Marmara University. Istanbul, Turkey, - 1/1/1991
Press Mentions
- World Lung Cancer Day: Celebrating Advances in Care, Patient ResilienceAugust 1st, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: